MedPath

Isoniazid

Generic Name
Isoniazid
Brand Names
Isonarif, Isotamine, Isotamine B, Rifamate, Rifater
Drug Type
Small Molecule
Chemical Formula
C6H7N3O
CAS Number
54-85-3
Unique Ingredient Identifier
V83O1VOZ8L
Background

Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis.

Indication

Isoniazid is used for the treatment of all forms of tuberculosis in which organisms are susceptible. It is also used in combination with rifampin and pyrazinamide.

Associated Conditions
Active Tuberculosis, Mycobacterium kansasii infection, Late phase Tuberculosis
Clinical Trials
Related News

Vaginal Dinoprostone Versus Isonicotinic Acid Hydrazide Prior to Diagnostic Office Hysteroscopy

Not Applicable
Conditions
Postmenopausal Bleeding
Interventions
First Posted Date
2020-08-05
Last Posted Date
2021-09-29
Lead Sponsor
Aswan University Hospital
Target Recruit Count
200
Registration Number
NCT04500496
Locations
🇪🇬

Aswan University Hospital, Aswan, Egypt

Isonicotinic Acid Hydrazide (INH) Pretreatment With Misoprostol Versus Misoprostol Alone in Missed Abortion

Not Applicable
Conditions
IUCD Complication
Interventions
First Posted Date
2020-08-05
Last Posted Date
2020-08-05
Lead Sponsor
Aswan University Hospital
Target Recruit Count
240
Registration Number
NCT04500002
Locations
🇪🇬

Aswan University Hospital, Aswan, Egypt

Vaginal Isonicotinic Acid Hydrazide Administration Prior to Intrauterine Device Insertion

Phase 4
Completed
Conditions
IUCD Complication
Interventions
Drug: Placebo Comparator
First Posted Date
2020-08-05
Last Posted Date
2021-09-29
Lead Sponsor
Aswan University Hospital
Target Recruit Count
130
Registration Number
NCT04500015
Locations
🇪🇬

Aswan University Hospital, Aswan, Egypt

Vaginal Isonicotinic Acid Hydrazide (INH) Administration Prior to T380A Intrauterine Device Insertion

Phase 4
Completed
Conditions
IUCD Complication
Interventions
Drug: Placebo Comparator
First Posted Date
2020-08-05
Last Posted Date
2021-08-09
Lead Sponsor
Aswan University Hospital
Target Recruit Count
220
Registration Number
NCT04499989
Locations
🇪🇬

Aswan University Hospital, Aswan, Egypt

Vaginal Isonicotinic Acid Hydrazide Administration Prior to Insertion Levonorgestrel-releasing Intrauterine System

Phase 4
Completed
Conditions
IUCD Complication
Interventions
Drug: Placebo Comparator
First Posted Date
2020-08-05
Last Posted Date
2022-05-13
Lead Sponsor
Aswan University Hospital
Target Recruit Count
220
Registration Number
NCT04500028
Locations
🇪🇬

Aswan University Hospital, Aswan, Egypt

Vaginal Isonicotinic Acid Hydrazide Prior to Diagnostic Office Hysteroscopy in Primarily Infertile Patients

Phase 4
Completed
Conditions
Infertility, Female
Interventions
Drug: Placebo
First Posted Date
2020-08-05
Last Posted Date
2021-09-29
Lead Sponsor
Aswan University Hospital
Target Recruit Count
150
Registration Number
NCT04500522
Locations
🇪🇬

Aswan University Hospital, Aswan, Egypt

Treatment Shortening of Drug-Sensitive Pulmonary Tuberculosis Using High Dose Rifampicin (Hi-DoRi-3)

Phase 3
Not yet recruiting
Conditions
Tuberculosis, Pulmonary
Interventions
First Posted Date
2020-07-24
Last Posted Date
2020-07-24
Lead Sponsor
Seoul National University Hospital
Target Recruit Count
926
Registration Number
NCT04485156
Locations
🇰🇷

Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine and Lung Institute of Medical Research Center, Seoul National University College of Medicine, Seoul, Korea, Republic of

Clofazimine- and Rifapentine-Containing Treatment Shortening Regimens in Drug-Susceptible Tuberculosis: The CLO-FAST Study

Phase 2
Completed
Conditions
HIV
Tuberculosis
Interventions
Dietary Supplement: Pyridoxine (vitamin B6)
First Posted Date
2020-03-17
Last Posted Date
2024-07-03
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
104
Registration Number
NCT04311502
Locations
🇭🇹

Les Centres GHESKIO Clinical Research Site (GHESKIO-INLR) CRS, Port-au-Prince, Haiti

🇿🇼

Milton Park CRS, Harare, Zimbabwe

🇿🇦

CAPRISA eThekwini CRS, Durban, Kwa Zulu Natal, South Africa

and more 3 locations

Drug-Drug Interactions Between Rifapentine and Dolutegravir in HIV/LTBI Co-Infected Individuals

Phase 2
Suspended
Conditions
HIV Infection
LTBI
Interventions
Drug: Antiretroviral Therapy (ART)
Dietary Supplement: Pyridoxine (Vitamin B6)
First Posted Date
2020-02-17
Last Posted Date
2024-08-12
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
37
Registration Number
NCT04272242
Locations
🇿🇦

University of Cape Town Lung Institute (UCTLI) CRS, Cape Town, South Africa

🇺🇸

University of California HIV/AIDS CRS, San Francisco, California, United States

🇺🇸

Houston AIDS Research Team CRS, Houston, Texas, United States

and more 7 locations

Efficacy and Safety of Intravenous Treatment of Tuberculosis

Terminated
Conditions
Tuberculosis, Pulmonary
Interventions
First Posted Date
2019-11-04
Last Posted Date
2019-11-07
Lead Sponsor
Yuria-Pharm
Target Recruit Count
166
Registration Number
NCT04150367
Locations
🇺🇦

Regional Antituberculosis Dispensary, Kherson, Ukraine

🇺🇦

Regional Clinical Antituberculosis Dispensary, Sumy, Ukraine

🇺🇦

Regional phthisiopulmonary center, Ivano-Frankivs'k, Ukraine

and more 5 locations
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy